G

Genomed SA
WSE:GEN

Watchlist Manager
Genomed SA
WSE:GEN
Watchlist
Price: 27.2 PLN 3.82% Market Closed
Market Cap: 35.9m PLN
Have any thoughts about
Genomed SA?
Write Note

P/OCF
Price to OCF

26.8
Current
30.1
Median
23.4
Industry
Lower than median
Higher than industry value

Price to Operating Cash Flow (P/OCF) ratio is a valuation multiple that measures the value of a company’s market capitalization relative to the operating cash flow it generates. Some analysts prefer P/OCF over P/E since earnings can be more easily manipulated than cash flows.

P/OCF
26.8
=
Market Cap
34.6m PLN
/
Operating Cash Flow
1.3m PLN
All Countries
Close
Market Cap P/OCF
PL
Genomed SA
WSE:GEN
34.6m PLN 26.8
FR
Pharnext SCA
OTC:PNEXF
6T USD -236 773.4
US
Abbvie Inc
NYSE:ABBV
299.8B USD 18.2
US
Amgen Inc
NASDAQ:AMGN
159.1B USD 21.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
124.7B USD -132.1
US
Gilead Sciences Inc
NASDAQ:GILD
114.8B USD 11.5
US
Epizyme Inc
F:EPE
94.1B EUR -475.1
AU
CSL Ltd
ASX:CSL
137.3B AUD 32
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
86.2B USD 20.3
US
Seagen Inc
F:SGT
39.3B EUR -76.7
NL
argenx SE
XBRU:ARGX
34B EUR -137.9

P/OCF Forward Multiples

Forward P/OCF multiple is a version of the P/OCF ratio that uses forecasted operating cash flow for the P/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/OCF
N/A
2-Years Forward
P/OCF
N/A
3-Years Forward
P/OCF
N/A

See Also

Discover More